Three things to know:
1. Axial spondyloarthritis primarily affects the sacroiliac joints and the spine, resulting in chronic inflammatory back pain and fatigue.
2. The drug is cleared to treat patients who show signs of inflammation but have not responded to conventional therapy.
3. This is the fourth indication for Taltz. Health Canada has also cleared the drug for plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
More articles on spine:
A simple solution to the health insurance marketplace: Authorize interstate competition
Where orthopedic PE partnerships stand in 2020
Facet joint replacement, stem cells & AR: 9 surgeons discuss new technologies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
